Berdazimer Sodium is a small molecule commercialized by Novan, with a leading Pre-Registration program in Molluscum Contagiosum. According to Globaldata, it is involved in 7 clinical trials, which were completed. GlobalData uses proprietary data and analytics to provide a complete picture of Berdazimer Sodium’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Berdazimer Sodium is expected to reach an annual total of $191 mn by 2033 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Berdazimer Sodium Overview

SB-206 is under development for the treatment of molluscum contagiosum caused by the molluscipoxvirus and Genital Warts (Condylomata Acuminata).The drug candidate is applied topically as gel.

It is a nitric oxide-releasing anti-viral new chemical entity. It is developed based on NITRICIL technology delivering nitric oxide by storing the gaseous species on large polymers that result in timed-release of nitric oxide. It was also under development for the treatment of HPV associated sexually transmitted infection (HPV 16 & 18) and perianal warts caused by human papillomavirus (HPV 6 & 11).

Novan Overview

Novan is a clinical development-stage biotechnology company that focuses on leveraging nitric oxide’s immunomodulatory and anti-microbial mechanisms of action for the treatment of diseases with unmet needs. The company’s products find application in the treatment of dermatology disorders, gastroenterology and women’s health. Its pipeline products focus on treating acne vulgaris, external genital warts, onychomycosis, psoriasis, molluscum, tinea pedis, human papillomavirus (HPV) and atopic dermatitis. Novan uses its proprietary technology Nitricil to develop new chemical entities with sustained delivery of nitric oxide. It works in Collaboration with academic institutions, Universities, private and public companies. Novan is headquartered in Morrisville, North Carolina, the US.

The company reported revenues of (US Dollars) US$3 million for the fiscal year ended December 2021 (FY2021), a decrease of 39.9% over FY2020. The operating loss of the company was US$29 million in FY2021, compared to an operating loss of US$30.2 million in FY2020. The net loss of the company was US$29.7 million in FY2021, compared to a net loss of US$29.3 million in FY2020. The company reported revenues of US$5.1 million for the third quarter ended September 2022, a decrease of 16.9% over the previous quarter.

For a complete picture of Berdazimer Sodium’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.